U.S. markets closed

Acerus Pharmaceuticals Corporation (ASP.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.04000.0000 (0.00%)
At close: 2:53PM EST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0400
Open0.0400
Bid0.0400 x N/A
Ask0.0450 x N/A
Day's Range0.0400 - 0.0450
52 Week Range0.0300 - 0.1300
Volume97,411
Avg. Volume301,346
Market Cap61.504M
Beta (5Y Monthly)1.00
PE Ratio (TTM)N/A
EPS (TTM)-0.0290
Earnings DateNov 03, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Read This Before Selling Acerus Pharmaceuticals Corporation (TSE:ASP) Shares
      Simply Wall St.

      Read This Before Selling Acerus Pharmaceuticals Corporation (TSE:ASP) Shares

      It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

    • Acerus Announces Waiver of Q4 Financial Covenant in Credit Agreement
      Business Wire

      Acerus Announces Waiver of Q4 Financial Covenant in Credit Agreement

      Acerus Pharmaceuticals Corporation ("Acerus" or the "Company") (TSX: ASP, OTCQB: ASPCF) today announced that it received a waiver letter from SWK Funding LLC ("SWK") related to the required Minimum Revenue Covenant for Q4-2020 in its existing credit facility with Acerus.

    • Acerus Announces Details of Previously Completed Rights Offering
      Business Wire

      Acerus Announces Details of Previously Completed Rights Offering

      Acerus Pharmaceuticals Corporation ("Acerus" or the "Company") (TSX: ASP, OTCQB: ASPCF) is pleased to announce that, further to its press release dated November 25, 2020 with respect to the completion of Acerus’ rights offering (the "Rights Offering"), Acerus issued 526,600,000 common shares of Acerus ("Common Shares") under the Rights Offering at a price of $0.025 per share for gross proceeds of approximately $13,165,000.